This Western Europe-based investment firm has been active for over two decades and manages multi-billion in assets under management. The firm takes a sector-agnostic approach, investing across a broad spectrum including enterprise software, fintech, consumer technologies, deeptech, and life sciences.
Typical equity investments range from $1 million to $10 million, and the firm expects to make several new investments annually. While companies must maintain a local operational presence in the firm’s home country, they may also have international footprints.
In the life sciences and biotech space, the firm adopts a wide-angle lens, looking for companies developing drug discovery platforms, synthetic biology innovations, and enabling research technologies.
The firm is open to investing in pre-revenue companies, and is supportive of both emerging and experienced founding teams. It frequently invests at the early growth stage, often in syndicate with other institutional investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment